<DOC>
	<DOCNO>NCT01745094</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy concomitant use mirabegron patient overactive bladder treatment solifenacin .</brief_summary>
	<brief_title>A Study Evaluate Effect Mirabegron + Solifenacin Overactive Bladder Patients</brief_title>
	<detailed_description>The duration study total 18 week include 2-week screening period 16 week treatment period . At week 8 visit , dose mirabegron increase base agreement subject mirabegron , opinion investigator sub-investigator , fully effective .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Female : postmenopausal OAB outpatient Male : OAB outpatient wish child future Patient treatment solifenacin stable dose daily least 4 week prior study Patient total OABSS score ≥3 point Question 3 score ≥2 point Patient residual urine volume ≥100 mL maximum flow rate &lt; 5 mL/s , patient benign prostatic hyperplasia , low urinary tract obstruction Patient serious heart disease ( myocardial infarction , cardiac failure , uncontrolled angina pectoris , serious arrhythmia , use pacemaker , etc . ) , liver disease , kidney disease , immunological disease , lung disease , etc . patient malignant tumor ( except malignant tumor treat least 5 start screen period risk recurrence ) Patient receive surgical therapy may affect urinary tract function within 24 wk start screening period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mirabegron</keyword>
	<keyword>solifenacin</keyword>
</DOC>